Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk BioPharma DiveFoundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive Foundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience. RegulatoryMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly bags FDA okay for Wegovy pill rival orforglipronNext: Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
